Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with...